iRhythm (IRTC: NASDAQ) Investor Relations Material

Overview

iRhythm Technologies, a San Francisco-based digital healthcare company, has been making significant strides in the field of ambulatory electrocardiogram (ECG) monitoring products aimed at patients at risk of arrhythmias in the US market. Its innovative Zio service is a convenient, easy-to-use wearable biosensor that combines wireless capabilities with a cloud-based data analytics platform helping physicians to monitor and diagnose arrhythmias in their patients. The company's flagship products Zio XT and AT monitors are single-use, wire-free, and wearable patch-based biosensors that can efficiently record a patient's heartbeats and ECG data, aiding physicians in their treatment decisions. iRhythm Technologies is also partnering with Verily Life Sciences to develop various next-generation atrial fibrillation screening, detection, or monitoring products, and this collaboration agreement is expected to yield impressive results.